Skip to main content

About Leica Biosystems

150+ Years of Innovation

As a global leader in anatomic pathology solutions, Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis.

Our Mission

Advancing Cancer Diagnostics, Improving Lives


Our Vision

From translational research to patient treatment, we envision a world where comprehensive insights enrich cancer diagnosis and offer reassurance to all patients.

News & Events



Update on Leica Biosystems Progress Toward In Vitro Diagnostics Regulation (IVDR) Compliance

Leica Biosystems is pleased to announce its latest update for In Vitro Diagnostics Regulation (IVDR) certification from the notified body BSI for the immunohistochemistry (IHC) portfolio.

Read More

Leica Biosystems Launches BOND-PRIME Advanced Staining Solution to Accelerate Diagnostic Productivity

Powered by Universal Access, BOND-PRIME Enables Labs to Seamlessly Adapt to Any Incoming Workflows NUSSLOCH, Germany (April 19) – Leica Biosystems announce the European launch of BOND-PRIME.

Read More

Leica Biosystems Strengthens Portfolio with FDA Clearance of Class II Mismatch Repair (MMR) Panel

The BOND MMR Antibody Panel is now available for clinical use on BOND-III and BOND-MAX Immunohistochemistry (IHC) automated instruments.

Read More

Leica Biosystems at a Glance

About US

150+ Years of Innovation

2012 - Present

New Era of Science & Technology

2005 - 2011

Global Expansion Accelerates

1989 - 2004

Structuring for Comprehensive Workflow

1930 - 1988

Novel Products Drive Company Growth

1900 - 1930

Microtomy Technology Advances Amidst Wartime Realities

1872 - 1899

The Creation of the Microtome and the Early Years of R. Jung GMBH

Download the booklet